Article Text

PDF
▾ Etodolac - a new NSAID for rheumatoid arthritis

Abstract

Etodolac (Lodine-Ayerst; Ramodar-Wyeth) is the first new non-steroidal anti-inflammatory drug (NSAID) to be licensed in Britain for over three years. The licence is for use in rheumatoid arthritis (RA) only. Etodolac is claimed to be as effective as high-dose aspirin with no more unwanted effects than placebo. Does the clinical evidence support this claim?

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.